Improvement in symptoms at ≤ 3 months · carpal tunnel syndrome
1 finding from 1 review
Improvement in function at ≤ 3 months · carpal tunnel syndrome
1 finding from 1 review
Improvement in symptoms at > 3 months · carpal tunnel syndrome
1 finding from 1 review
Improvement in neurophysiological parameters at ≤ 3 months · carpal tunnel syndrome
1 finding from 1 review
Requirement for carpal tunnel surgery · carpal tunnel syndrome
Local corticosteroid injection (LCI) probably leads to lower requirement for carpal tunnel surgery compared with saline no treatment or placebo (moderate certainty).
1 finding from 1 review
Improvement in quality of life · carpal tunnel syndrome
1 finding from 1 review
Adverse events · carpal tunnel syndrome
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in neuropathy symptoms · people with DPN
1 finding from 1 review
Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with DPN
1 finding from 1 review
Change in any validated quality of life score · people with DPN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications of DPN · people with DPN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with DPN
Alpha‐lipoic acid showed no clear difference in adverse events leading to cessation of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Induction of labour · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with an improvement in disability scale used in the original study · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants with an improvement in disability scale… compared with placebo (low certainty).
1 finding from 1 review
RR 3 [0.89, 10.12]
18 participants
Low
Proportion of participants with an improvement of muscle strength · people with multifocal motor neuropathy
IVIg may leads to higher proportion of participants with an improvement of muscle strength compared with placebo (low certainty).
1 finding from 1 review
RR 11 [2.86, 42.25]
27 participants
Low
Proportion of participants with an improvement in disability at 12 months or later · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found